CBD restores sleep and reduces seizures in Angelman syndrome

This study investigated whether cannabidiol (CBD), a non-intoxicating cannabinoid, could help treat sleep and seizure problems in mice with Angelman syndrome, a rare genetic disorder. Researchers used mice lacking the Ube3a gene and administered CBD chronically to observe its effects. The results showed that CBD significantly improved multiple aspects of sleep, including increasing rapid-eye movement (REM) sleep during nighttime hours and restoring a natural midday rest period known as "Siesta," which indicates restored normal sleep-wake patterns.

Beyond sleep improvements, the study found that CBD reduced spontaneous seizures that developed after the mice were exposed to a seizure-inducing stimulus. This is particularly significant because both sleep problems and seizures are major symptoms affecting people with Angelman syndrome. The findings suggest that CBD's therapeutic potential extends beyond anecdotal reports and warrants further clinical investigation in human patients with this condition.

These results support the growing scientific interest in CBD-based treatments for neurological and sleep disorders. For cannabis users and families seeking alternatives to traditional medications, this research provides preliminary evidence that CBD may offer relief for complex symptoms when conventional treatments fall short. However, more research—particularly human clinical trials—is needed before CBD can be recommended as a standard treatment for Angelman syndrome.